- Report
- May 2018
- 15 Pages
Global
- Report
- June 2021
Global
From €3814EUR$4,000USD£3,269GBP
- Report
- September 2022
- 62 Pages
Global
From €4720EUR$4,950USD£4,045GBP
- Report
- January 2021
- 120 Pages
Global
From €2384EUR$2,500USD£2,043GBP
- Report
- May 2023
- 220 Pages
Global
From €3337EUR$3,500USD£2,860GBP
- Report
- October 2022
- 200 Pages
Global
From €2813EUR$2,950USD£2,411GBP
- Report
- September 2018
- 15 Pages
Global
- Report
- August 2018
- 15 Pages
Global
- Report
- April 2018
- 15 Pages
Global
- Report
- December 2020
- 70 Pages
From €2002EUR$2,100USD£1,716GBP
€2860EUR$3,000USD£2,452GBP
- Report
- December 2020
- 114 Pages
From €2002EUR$2,100USD£1,716GBP
€2860EUR$3,000USD£2,452GBP
- Report
- December 2020
- 117 Pages
Middle East, Africa
From €2002EUR$2,100USD£1,716GBP
€2860EUR$3,000USD£2,452GBP
- Report
- October 2020
- 136 Pages
Europe
From €2002EUR$2,100USD£1,716GBP
€2860EUR$3,000USD£2,452GBP
- Report
- October 2020
- 133 Pages
Asia Pacific
From €2002EUR$2,100USD£1,716GBP
€2860EUR$3,000USD£2,452GBP
- Report
- October 2020
- 123 Pages
North America
From €2002EUR$2,100USD£1,716GBP
€2860EUR$3,000USD£2,452GBP
- Report
- August 2020
- 183 Pages
Global
From €3037EUR$3,185USD£2,603GBP
€4338EUR$4,550USD£3,718GBP
- Report
- December 2023
- 80 Pages
United Kingdom
From €2474EUR$2,595USD£2,121GBP
From €2474EUR$2,595USD£2,121GBP
- Report
- December 2023
- 80 Pages
Poland
From €2474EUR$2,595USD£2,121GBP
- Report
- December 2023
- 80 Pages
Argentina
From €2474EUR$2,595USD£2,121GBP
RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more